Purpose of Review We aim to summarize the current state of art about the possible use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative treatment. In addition, we aim to provide a snapshot about the clinical implication of biomarkers use for follow-up planification. Recent Findings A wide variety of biomarkers have been proposed. RCC biomarkers have been individuated in tumoral tissue, blood, and urine. A variety of molecules, including proteins, DNA, and RNA, warrant a good accuracy for RCC recurrence and progression prediction. Their use in prediction models might warrant a better patients' risk stratification. Future prognostic models will probably include a combination of classical features (tumor grade, stage, etc.) and novel biomarkers. Such models might allow a more accurate treatment and follow-up planification.

Marchioni, M., Rivas, J.g., Autran, A., Socarras, M., Albisinni, S., Ferro, M., et al. (2021). Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art. CURRENT UROLOGY REPORTS, 22(6) [10.1007/s11934-021-01050-0].

Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art

Albisinni S.;Papalia R.;
2021-01-01

Abstract

Purpose of Review We aim to summarize the current state of art about the possible use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative treatment. In addition, we aim to provide a snapshot about the clinical implication of biomarkers use for follow-up planification. Recent Findings A wide variety of biomarkers have been proposed. RCC biomarkers have been individuated in tumoral tissue, blood, and urine. A variety of molecules, including proteins, DNA, and RNA, warrant a good accuracy for RCC recurrence and progression prediction. Their use in prediction models might warrant a better patients' risk stratification. Future prognostic models will probably include a combination of classical features (tumor grade, stage, etc.) and novel biomarkers. Such models might allow a more accurate treatment and follow-up planification.
2021
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/24 - UROLOGIA
English
Renal cell carcinoma
miRNA
Biomarkers
Liquid biopsy
Marchioni, M., Rivas, J.g., Autran, A., Socarras, M., Albisinni, S., Ferro, M., et al. (2021). Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art. CURRENT UROLOGY REPORTS, 22(6) [10.1007/s11934-021-01050-0].
Marchioni, M; Rivas, Jg; Autran, A; Socarras, M; Albisinni, S; Ferro, M; Schips, L; Scarpa, Rm; Papalia, R; Esperto, F
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/310335
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 24
social impact